2nd Edition of Global Conference on Surgery and Anesthesia

September 28-30, 2020 | Paris, France

Campanile Roissy-En-France Hotel
Roissy Park Activity Area - Allee Des Vergers 95700 Roissy In France
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Whatsapp: +1 434 381 1007
Email: contact@surgery-conferences.com
September 28-30, 2020 | Paris, France


Potential Speaker for Anesthesia Conferences 2020 - Agnese Ozolina
Rigas Stradins University ,Lativia
Title : Multi-route applications of tranexamic acid to reduce blood loss in elective surgery – risks and benefits


Blood loss control with tranexamic acid (TXA) may be a preferable alternative in elective surgery. Many randomized controlled trials and meta-analysis have been identified the efficacy of TXA. There is still no uniform standard for the best method of administration and dose of TXA. When compare IV administration of TXA with topical there is no significant difference in overall or for orthopaedic procedures. However, to reduce the potential risk of thromboembolic complications and extended the effect of TXA postoperatively, the topical administration of TXA can be considered. It may give notable clinical relevant effect for those where wound is accessible and for high thrombotic risk patients. Moreover, intrapericardial use of TXA in patients undergoing cardiac surgery can decrease postoperative bleeding without increasing the risk of postoperative seizures. In addition, topical TXA could reduce the postoperative swelling and thus the pain which caused by swelling can be reduced. In conclusion, there are no major differences between topical and intravenous tranexamic acid with respect to safety and efficacy, and both are superior to placebo with regards to blood loss and transfusion requirements. The effect does not appear to be dose-dependent in topical administration. There exist a lack of a relationship between topical TXA administration and an increased risk of adverse events including thromboembolism. Outside of orthopaedic surgery, the comparison of topically administered tranexamic acid to intravenously administered tranexamic acid warrants further exploration.


Dr. med, PhD Agnese Ozolina studied in R?gas Stradi?š University Medical faculty and graduated as MD in 2004. Then she continued training in Anaesthesia and Intensive Care medicine becoming a specialist in 2010. My greatest interest has always been directed toward to the management of bleeding and thrombosis. A growing interest in research and lecturing, led me to a prospective observational study on genetically determinated fibrinolytic bleeding after cardiac surgery, which founded the basis of my dissertation and PhD degree in 2013. Consequently, several publications were reported. Parallel, I have an experience as invited lecturer in local and international meetings. As assistant professor of R?gas Stradi?š University I am involved in teaching of physiological and pathophysiological aspects of haemostasis in local and international students. Presently, I am the head of Anaesthesiology at Riga East University hospital. Paralelly, I am mostly involved in the regional anesthesia techniques and management of haemostasis in orthopaedic and microvascular free flap surgery patients, including such essentials as individual goal-directed treatment based on ROTEM analysis for bleeding as well as for anticoagulation management.